Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.

International journal of molecular sciences·2026
Same author

Precision oncology in rare tumors: Have the orphans been adopted?

Med (New York, N.Y.)·2026
Same author

Personalized cancer vaccines and their integration with standard of care modalities.

Cancer treatment reviews·2026
Same author

Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Journal for immunotherapy of cancer·2025
Same author

Biliary tract cancers: advances in diagnostic and management.

Exploration of targeted anti-tumor therapy·2025

Related Experiment Video

Updated: May 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

981

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.

Hiba Mechahougui1, James Gutmans1, Roumaïssa Gouasmi2

  • 1Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland.

International Journal of Molecular Sciences
|May 7, 2025
PubMed
Summary

BRAF V600E mutations drive cancers like melanoma. Targeted therapies improve survival, but resistance necessitates exploring combinations with immunotherapy and understanding tumor biology.

Keywords:
BRAFmolecular oncologyprecision oncologytargeted therapytissue specificity

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.2K

Related Experiment Videos

Last Updated: May 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

981
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • BRAF mutations, particularly BRAF V600E, are key drivers in various cancers, including melanoma, colorectal, and non-small-cell lung cancer.
  • Targeted therapies inhibiting BRAF and MEK have shown efficacy, especially in melanoma, improving patient survival rates.

Purpose of the Study:

  • To review the role of BRAF mutations in cancer and the challenges associated with targeted therapies.
  • To explore emerging strategies, including immunotherapy combinations, to overcome treatment resistance.
  • To emphasize the importance of tumor origin and microenvironment in therapeutic response.

Main Methods:

  • Literature review of BRAF mutations in cancer.
  • Analysis of targeted therapy mechanisms and resistance pathways.
  • Exploration of combination strategies and future research directions.

Main Results:

  • BRAF V600E is a significant therapeutic target, with inhibitors improving outcomes in melanoma.
  • Resistance to BRAF/MEK inhibitors arises from secondary mutations, alternative pathway activation (PI3K/AKT), and tumor microenvironment changes.
  • Metastatic colorectal cancer with BRAF mutations shows poor prognosis and chemoresistance.

Conclusions:

  • BRAF inhibitors offer benefits but face resistance challenges.
  • Combining BRAF inhibitors with immunotherapy is a promising strategy to enhance treatment efficacy.
  • Understanding cancer-specific biology, including tissue of origin and tumor microenvironment, is crucial for optimizing targeted therapies.